文献速递心境障碍焦虑、强迫与应激相关障碍

健康志愿者微剂量麦角酸二乙酰胺的急性情绪提升特性:家庭给药随机对照试验

Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
PubMed 文献 · Biol Psychiatry · 2023-03-28

结果显示,LSD组在给药日相比非给药日在创造力、连接感、精力、幸福感、易怒性和健康感评分上有可信改善(后验概率>99%),但基线至6周评估期间问卷或认知任务均无可信变化,且LSD组有4人因治疗相关焦虑退出。

要点

  • 微剂量LSD在健康男性中相对安全,但存在焦虑风险,LSD组4人因治疗相关焦虑退出。
  • 给药日相比非给药日,创造力、连接感、精力、幸福感、易怒性和健康感评分有可信改善(后验概率>99%)。
  • 基线至6周评估期间,所有问卷和认知任务均未显示可信变化。

核心结论

  • 微剂量LSD在健康成年男性中相对安全,但存在焦虑风险。
  • 微剂量LSD可产生短暂的情绪提升效应,但不足以在健康成人中促成整体情绪或认知的持久改变。

研究设计与样本

  • 随机对照试验,健康男性志愿者随机分为LSD组(n=40)和安慰剂组(n=40)。
  • 每3天给药一次,共14次,持续6周;首次剂量在监督实验室环境中给予,其余剂量在自然环境中自行给药。

主要发现

  • 最显著的不良事件为治疗相关焦虑,导致LSD组4名参与者退出。
  • 每日问卷显示,给药日相比非给药日,创造力、连接感、精力、幸福感、易怒性和健康感评分有可信改善(后验概率>99%),控制基线期望后效应仍存在。
  • 基线至6周评估期间,无问卷或认知任务显示可信变化。

关键数值与推荐

  • 给药日相比非给药日,创造力、连接感、精力、幸福感、易怒性和健康感评分改善的后验概率>99%。
  • LSD组4名参与者因治疗相关焦虑退出。

临床怎么用

  • 微剂量LSD在健康成人中可能产生短暂情绪提升,但不应期望持久的情绪或认知改善。
  • 临床使用需关注焦虑风险,未来临床试验应使用活性安慰剂控制安慰剂效应,并进行剂量滴定以调整个体间药物反应差异。

局限性

  • 研究对象为健康男性志愿者,结果可能不适用于临床人群或女性。
  • 首次剂量在实验室监督下给药,其余在自然环境中自行给药,可能影响生态效度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity. METHODS: Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups and received 14 doses of either 10 μg LSD or an inactive placebo every 3 days for 6 weeks. First doses were given in a supervised laboratory setting, with other doses self-administered in a naturalistic setting. Results of safety data, blinding, daily questionnaires, expectancy, and pre-/postintervention psychometrics and cognitive tasks are presented here. RESULTS: The most notable reported adverse event was treatment-related anxiety, which prompted the withdrawal of 4 participants from the LSD group. Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness on dose days compared with nondose days, and these effects remained when controlling for preintervention expectancy. No questionnaire or cognitive task showed a credible change between baseline and 6-week assessment time points. CONCLUSIONS: Microdosing LSD appears to be relatively safe in healthy adult men, notwithstanding a risk of anxiety. While microdosing elicited transient increases in scales associated with mood-elevating effects, it was not sufficient to promote enduring changes to overall mood or cognition in healthy adults. Future microdosing trials in clinical populations will require the use of active placebos to control for placebo effects and dose titration to adjust for interindividual variability in drug response.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Murphy RJ, Sumner R, Evans W, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biol Psychiatry. 2023. PMID: 36997080. doi:10.1016/j.biopsych.2023.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。